Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.78 |
| ▸ | DRD2 | P14416 | 4/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.78 |
| ▸ | DRD1 | P21728 | 4/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.78 |
| ▸ | HTR2A | P28223 | 4/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.78 |
| ▸ | HRH1 | P35367 | 4/20 | 0.78 |
| ▸ | DRD3 | P35462 | 4/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | TP53 | P04637 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perazine SCHEMBL147165 | 1.00 | KDM1A (1.00) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL2237726 | 0.98 | KDM1A (0.97) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL6644457 | 0.98 | KDM1A (0.97) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL6859184 | 0.97 | KDM1A (0.94) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL10531680 | 0.92 | KDM1A (0.84) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL10973127 | 0.91 | KDM1A (0.84) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL2615404 | 0.89 | KDM1A (0.80) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL7654455 | 0.88 | CYP3A4 (0.82) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL7533558 | 0.88 | KDM1A (0.78) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL220703 | 0.88 | MAPT (0.82) | KDM1AHTR1AADRA2ACHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3192499-B1 | CELLULOSE FIBRE BASED SUPPORT MATRICES FOR LAYERED PRODUCTS FOR ORAL AND PERORAL APPLICATION AND THEIR PREPARATION | GLATT GMBH (DE) | 2023-11-29 | — | — | EP | claimed |
| US-12629094-B2 | System, software and methods of using software for predicting efficacy of alzheimer's disease treatments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4712964-A1 | COMPOUNDS AND FORMULATIONS USEFUL AS VACCINE ADJUVANTS | Merck Sharp & Dohme LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12410474-B2 | Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient | NORTHWESTERN UNIVERSITY (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | SYMRISE AG (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-2938328-B1 | MONOLITHIC PHARMACEUTICAL FORM FOR MODIFIED RELEASE OF AN ACTIVE INGREDIENT COMBINATION | HENNIG ARZNEIMITTEL GMBH&CO KG (DE) | 2023-07-05 | — | — | EP | disclosed |
| CN-114478609-B | Method for using thiophenol photocatalyst in defluorination alkylation or defluorination protonation reaction | 中国科学技术大学 | 2023-06-16 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11401305-B2 | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | XL-PROTEIN GMBH (DE) | 2022-08-02 | — | — | US | disclosed |
| WO-2022133184-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220177970-A1 | METHODS, KITS, AND DEVICES FOR DIAGNOSING, PROGNOSING, AND TREATING PSYCHIATRIC DISORDERS IN A PATIENT | NORTHWESTERN UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| CN-114478609-A | Method for applying thiophenol photocatalyst to defluorination alkylation or defluorination protonation reaction | 中国科学技术大学 | 2022-05-13 | — | — | CN | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629094-B2 | System, software and methods of using software for predicting efficacy of alzheimer's disease treatments | MAPT, APP, PSEN2 | KDM1A 4649/4885HTR1A 567/4885ADRA2A 66/4885 |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | TAS2R5, TAS2R7, TAS2R8 | KDM1A 3113/4885HTR1A 1753/4885ADRA2A 4569/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | KDM1A 1695/4885HTR1A 2564/4885ADRA2A 3011/4885 |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | KDM1A 1695/4885HTR1A 2564/4885ADRA2A 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.